GLP-1 / IncretinWeight Management

Retatrutide

Retatrutide is an incretin-class research peptide investigated for its role in the gut–brain signaling that regulates appetite, satiety, and glucose handling. It is among the most actively studied compounds in modern metabolic science and is supplied here strictly as a characterized reference material for laboratory investigation.

Overview

Executive Summary

Research context: Retatrutide is studied primarily within weight management and energy research. All information below is presented for educational and reference purposes only.

Origins

Discovery History

1
1980s
Glucagon-like peptide-1 (GLP-1) is identified as a product of the proglucagon gene with potent incretin activity.
2
1990s
Researchers characterize GLP-1 receptor signaling in the pancreas, gut, and brain.
3
2000s
Long-acting analogs are engineered to resist DPP-4 degradation and extend half-life.
4
2010s–present
Dual and triple incretin agonists (GIP/GLP-1/glucagon) emerge as leading subjects of metabolic research.

How it works

Mechanism of Action

Receptor engagement

Binds incretin receptors (GLP-1 and, for dual/triple agonists, GIP and glucagon) expressed in the pancreas, gut, and central nervous system.

Satiety signaling

Modulates hypothalamic appetite circuits, studied for reductions in food intake and prolonged satiety.

Glucose-dependent response

Investigated for glucose-dependent insulinotropic activity, slowing gastric emptying and blunting post-prandial excursions.

Energy balance

Explored for downstream effects on energy expenditure and body composition over sustained exposure.

Fields of study

Areas of Scientific Research

Appetite & satiety

Central and peripheral regulation of hunger signaling.

Glycemic control

Glucose-dependent insulin dynamics and insulin sensitivity.

Body composition

Adiposity, lean mass retention, and metabolic set point.

Cardiometabolic markers

Lipid profiles and inflammatory signaling in metabolic models.

What's being studied now

Current Research

1
Comparative studies of mono-, dual-, and triple-receptor agonism on energy balance and body composition.
2
Investigation of gastric emptying and post-prandial glucose dynamics in controlled models.
3
Exploration of central appetite circuits and the durability of satiety signaling over sustained exposure.
4
Emerging interest in cardiometabolic and inflammatory markers beyond weight endpoints.

Important

Safety Information

For laboratory research use only — not for human or veterinary use.

Research use only

Retatrutide is supplied strictly as a laboratory research reference material. It is not a drug, supplement, or food, and is not intended for human or veterinary use, consumption, or therapeutic application.

Handling

Handle with appropriate personal protective equipment in a controlled laboratory environment. Avoid inhalation, ingestion, and contact with skin or eyes.

Not clinically evaluated

Statements describe areas of scientific investigation only. No claims of safety or efficacy in humans are made or implied, and the compound has not been evaluated by regulatory agencies for any use.

Qualified personnel

Intended for use only by qualified researchers and institutions familiar with the proper handling of research reference materials.

Handling

Storage

Lyophilized (unopened)

Stable at room temperature for short periods; store at -20°C for long-term stability.

After reconstitution

Refrigerate at 2–8°C and use within 2–4 weeks depending on the compound.

Protect from light & heat

Avoid repeated freeze–thaw cycles and prolonged light exposure.

Handling

For laboratory research use only; handle with appropriate protective equipment.

Sources

Scientific References

[1]
Drucker DJ. Mechanisms of action and therapeutic application of GLP-1. Cell Metabolism, 2018.
[2]
Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes, Obesity and Metabolism, 2018.
[3]
Coskun T, et al. Multi-receptor agonism in metabolic research. Molecular Metabolism, 2022.